Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Thrombosis Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2014.11.011PMID 25467081PMCID PMC4272916
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications.

  2014cited by this paper
• Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status

  2014cited by this paper
• Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus

  2014cited by this paper
• Microparticles: biomarkers and beyond.

  2013cited by this paper
• Microvesicles as risk markers for venous thrombosis

  2013cited by this paper
• Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome

  2013cited by this paper
• Platelet tissue factor: to be or not to be.

  2013cited by this paper
• Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study)

  2013cited by this paper
• Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity.

  2012cited by this paper
• Studies of microparticles in patients with the antiphospholipid syndrome (APS)

  2012cited by this paper
• Microparticles in cardiovascular disease pathophysiology and outcomes.

  2012cited by this paper
• Microvesicles: potential markers and mediators of endothelial dysfunction

  2012cited by this paper
• β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.

  2011cited by this paper
• Microparticles in Hemostasis and Thrombosis

  2011cited by this paper
• Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner.

  2011cited by this paper
• Antiphospholipid antibodies and the protein C pathway

  2010cited by this paper
• Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways

  2010cited by this paper
• Predictive value of tissue factor bearing microparticles in cancer associated thrombosis.

  2010cited by this paper
• Antiphospholipid syndrome.

  2010cited by this paper
• Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis

  2010cited by this paper
• Circulating microparticles and risk of venous thromboembolism.

  2009cited by this paper
• Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity

  2009cited by this paper
• In vivo inhibition of antiphospholipid antibody‐induced pathogenicity utilizing the antigenic target peptide domain I of β2‐glycoprotein I: proof of concept

  2009cited by this paper
• The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study

  2009cited by this paper
• Circulating procoagulant microparticles in patients with venous thromboembolism.

  2009cited by this paper
• Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer

  2008cited by this paper
• Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms

  2008cited by this paper
• Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C

  2008cited by this paper
• Current concepts on the pathogenesis of the antiphospholipid syndrome.

  2007cited by this paper
• Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts.

  2007cited by this paper
• Anti-β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts

  2007cited by this paper
• Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies.

  2007cited by this paper
• Platelet adhesion to dimeric β2‐glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apolipoprotein E receptor 2′

  2007cited by this paper
• Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V.

  2006cited by this paper
• Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies.

  2005cited by this paper
• Circulating platelet-derived microparticles in systemic lupus erythematosus

  2005cited by this paper
• Lupus anticoagulants and the risk of a first episode of deep venous thrombosis

  2005cited by this paper
• Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome

  2004cited by this paper
• Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin.

  2004cited by this paper
• E‐Selectin mediates pathogenic effects of antiphospholipid antibodies

  2003cited by this paper
• Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.

  2003cited by this paper
• The antiphospholipid syndrome.

  2003cited by this paper
• Molecular Pathogenesis of the Antiphospholipid Syndrome

  2002cited by this paper
• Antiphospholipid antibodies and the protein C pathway.

  2000cited by this paper
• In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.

  1999cited by this paper
• Lupus anticoagulants and antiphospholipid antibodies.

  1998cited by this paper
• Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation.

  1997cited by this paper
• Autoantibodies to Phospholipid-binding Plasma Proteins in Patients with Thrombosis and Phospholipid-reactive Antibodies

  1996cited by this paper
• Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

  1995cited by this paper
• The antiphospholipid syndrome

  1995cited by this paper
• Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis.

  1993cited by this paper
• A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with Infection

  1992cited by this paper
• Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells.

  1992cited by this paper
• Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin

  1991cited by this paper
• Detection of endothelial cell‐reactive immunoglobulin in patients with anti‐phospholipid antibodies

  1991cited by this paper
• Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

  1990cited by this paper
• Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.

  1990cited by this paper
• Cyclosporin-induced muscular toxicity.

  1990cited by this paper
• Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus.

  1988cited by this paper

• Obstetric antiphospholipid syndrome: Advances in pathogenesis.

  2026cites this paper
• Extracellular Vesicles Analysis as Possible Signatures of Antiphospholipid Syndrome Clinical Features

  2025cites this paper
• Analytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome.

  2025cites this paper
• Prevalence and Outcome of Cerebral Microbleeds in Antiphospholipid Syndrome

  2025cites this paper
• Association between extracellular vesicles (EVs) and thrombosis in antiphospholipid syndrome

  2025cites this paper
• Persistently High Platelet Factor 4 Levels in an Adolescent with Recurrent Late Thrombotic Complications after SARS-CoV-2 mRNA Vaccination

  2024cites this paper
• Combination of age-adjusted d-dimer, platelet distribution width and other factors predict preoperative deep venous thrombosis in elderly patients with femoral neck fracture

  2024cites this paper
• Low-Grade Activation of the Extrinsic Coagulation Pathway in Patients with Ulcerative Colitis

  2024cites this paper
• Antiphospholipid syndrome in children.

  2024cites this paper
• Antiphospholipid Syndrome: Insights into Molecular Mechanisms and Clinical Manifestations

  2024cites this paper
• Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

  2023cites this paper
• Small-Extracellular-Vesicle-Derived miRNA Profile Identifies miR-483-3p and miR-326 as Regulators in the Pathogenesis of Antiphospholipid Syndrome (APS)

  2023cites this paper
• 11,12-EET suppressed LPS induced TF expression and thrombus formation by accelerating mRNA degradation rate via strengthening PI3K-Akt signaling pathway and inhibiting p38-TTP pathway.

  2023cites this paper
• Interaction between endothelial cell-derived extracellular vesicles and monocytes: A potential link between vascular thrombosis and pregnancy-related morbidity in antiphospholipid syndrome.

  2023cites this paper
• Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome

  2022cites this paper
• Extracellular vesicles released upon stimulation with antiphospholipid antibodies: An actual direct procoagulant mechanism or a new factor in the lupus anticoagulant paradox?

  2022cites this paper
• Systemic lupus erythematosus and cardiovascular disease

  2022cites this paper
• Platelet- and endothelial-derived microparticles in the context of different antiphospholipid antibody profiles

  2022cites this paper
• Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury

  2022cites this paper
• Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome

  2021cites this paper
• Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges

  2021cites this paper
• Extracellular Vesicles: Intercellular Communication Mediators in Antiphospholipid Syndrome

  2021cites this paper
• Platelet distribution width is highly associated with thrombotic events in primary antiphospholipid syndrome

  2021cites this paper
• Platelet-derived extracellular vesicles promote the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes via CXCR2 signaling

  2021cites this paper
• Tissue injury—the biology

  2021cites this paper
• Characterization of Plasma-Derived Small Extracellular Vesicles Indicates Ongoing Endothelial and Platelet Activation in Patients with Thrombotic Antiphospholipid Syndrome

  2020cites this paper
• Antiphospholipid antibodies and extracellular vesicles in pregnancy

  2020cites this paper
• NETs in APS: Current Knowledge and Future Perspectives

  2020cites this paper
• Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review

  2020cites this paper
• Cell Membrane-Derived Microvesicles in Systemic Inflammatory Response.

  2018cites this paper
• Renal Involvement in Antiphospholipid Syndrome

  2018cites this paper
• Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis

  2018cites this paper
• Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis

  2017cites this paper
• β2-glycoprotein I and its antibodies involve in the pathogenesis of the antiphospholipid syndrome.

  2017cites this paper
• Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers

  2017cites this paper
• A importância de reconhecer a síndrome antifosfolípide na medicina vascular

  2017cites this paper
• Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

  2017cites this paper
• Double-stranded DNA induces a prothrombotic phenotype in the vascular endothelium

  2017cites this paper
• Extracellular Vesicles in the Antiphospholipid Syndrome

  2017cites this paper
• Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?

  2017cites this paper
• Estudio del efecto sobre la hemostasia de los distintos agentes terapéuticos utilizados en el tratamiento de la trombocitopenia inmune

  2017cites this paper
• Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis

  2016cites this paper
• Endothelial microparticles: Pathogenic or passive players in endothelial dysfunction in autoimmune rheumatic diseases?

  2016cites this paper
• Delineating the deranged immune system in the antiphospholipid syndrome.

  2016cites this paper
• The diversity of platelet microparticles

  2015cites this paper
• The role of microparticles in inflammation and transfusion: A concise review.

  2015cites this paper
• A novel pathway of cellular activation mediated by antiphospholipid antibody‐induced extracellular vesicles

  2015cites this paper
• A new cytofluorimetric approach to evaluate the circulating microparticles in subjects with antiphospholipid antibodies.

  2015cites this paper
• Circulating Microparticles Alter Formation, Structure, and Properties of Fibrin Clots

  2015cites this paper